retatrutide and heart ESC 2024: improves lipid cardiovascular risk profile in Phase II trial Why Does Retatrutide Increase Heart

But the body responds to precision, not force

The increase in heart rate in retatrutide trials is the side effect that regulators and clinicians are watching closely

Insulinotropic potency of GLP-1 decrease in T2DM

However, they should complement, not replace, a resistance training program

Studies Linking GLP-1 Medications to NAION Several peer-reviewed studies have confirmed an increased risk of NAION in patients taking GLP-1 drugs: Harvard Medical School & Mass General Brigham Study (JAMA Ophthalmology, 2024) 9% of diabetic patients taking semaglutide developed NAION, compared to 1.8% on other diabetes drugs (a 4-fold increased risk)

There is no definitive evidence supporting probiotics, digestive enzymes, or most other supplements specifically for GLP-1 nausea, though individual patients may report subjective benefit